secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0000917520-23-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q4 adj EPS $0.94, rev $398M; FY2023 guidance rev $1.60-1.62B, adj EPS $3.43-3.51
--------------------------------------------------------------------------------

- Q4 2022 revenues $398.0M (-1.8% reported, +2.9% organic); GAAP EPS $0.63, adj EPS $0.94.
- Full-year 2022 revenues $1,557.7M (+1.0% reported, +4.2% organic); GAAP EPS $2.16, adj EPS $3.36.
- FY2023 guidance: revenues $1,602M-$1,620M (organic growth 4.0%-5.2%), adj EPS $3.43-$3.51.
- Entered $150M accelerated share repurchase agreement with Goldman Sachs, expected to complete in H1 2023.
- Codman Specialty Surgical organic growth 1.8%; Tissue Technologies organic growth 5.0% in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/iart-20230222.htm
  HTML page:      https://secwatch.observer/filing/0000917520-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer